Trial Profile
Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With High Risk Multiple Myeloma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Fludarabine; Melphalan; Sirolimus; Tacrolimus; Tacrolimus
- Indications Multiple myeloma
- Focus Adverse reactions
- 18 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Mar 2022 Planned End Date changed from 1 Sep 2019 to 31 Dec 2022.
- 01 Aug 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.